

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4075889

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
WARNER CHILCOTT COMPANY, LLC		12/31/2015
RECEIVING PARTY DATA		
Name:	ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED	
Street Address:	CLONSHAUGH INDUSTRIAL ESTATE	
Internal Address:	COOLOCK	
City:	DUBLIN 17	
State/Country:	IRELAND	
PROPERTY NUMBERS Total: 87		
Property Type	Number	
Application Number:	13471275	
Application Number:	14474868	
Patent Number:	8314081	
Patent Number:	8710215	
Patent Number:	8822435	
Patent Number:	D562153	
Patent Number:	6667050	
Application Number:	12769293	
Patent Number:	9035052	
Patent Number:	8158798	
Patent Number:	7795241	
Patent Number:	7067505	
Patent Number:	7067504	
Patent Number:	7645459	
Patent Number:	8246989	
Patent Number:	8535718	
Patent Number:	7645460	
Patent Number:	7485319	
Patent Number:	8415331	
Application Number:	11454697	

PATENT

Property Type	Number
Patent Number:	7569560
Patent Number:	7935691
Patent Number:	8063030
Patent Number:	7704984
Patent Number:	6165513
Patent Number:	6569460
Patent Number:	7737133
Patent Number:	7928092
Application Number:	11454717
Patent Number:	8124595
Patent Number:	9132137
Patent Number:	8703187
Application Number:	10564031
Patent Number:	8962010
Application Number:	10472901
Patent Number:	8409614
Patent Number:	8409615
Application Number:	14645512
Application Number:	61794998
Application Number:	13325170
Patent Number:	5837724
Patent Number:	6653339
Patent Number:	8748476
Patent Number:	6670140
Patent Number:	7063954
Patent Number:	7572768
Application Number:	13893717
Patent Number:	6329354
Application Number:	11955072
Patent Number:	7825106
Patent Number:	6962908
Patent Number:	7572779
Patent Number:	7799771
Patent Number:	6936585
Patent Number:	7462597
Patent Number:	7192924
Patent Number:	7608701
Patent Number:	7897731

Property Type	Number
Patent Number:	7192923
Patent Number:	7632933
Application Number:	11977137
Application Number:	12868021
Patent Number:	7138405
Application Number:	14210850
Patent Number:	6893662
Patent Number:	8580302
Patent Number:	9089492
Application Number:	11096457
Patent Number:	6106864
Application Number:	14210630
Application Number:	61794813
Application Number:	14210680
Application Number:	14524512
Application Number:	61794906
Patent Number:	7002014
Patent Number:	6562974
Patent Number:	7105571
Patent Number:	6323241
Patent Number:	6693135
Patent Number:	5233053
Patent Number:	5096890
Patent Number:	8461138
Patent Number:	6410520
Patent Number:	6930188
Patent Number:	7696357
Patent Number:	8050873
Patent Number:	6841161

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-997-1000

Email: docket@feiplaw.com

Correspondent Name: FLOREK & ENDRES PLLC

Address Line 1: 1156 AVENUE OF THE AMERICAS

Address Line 4: NEW YORK, NEW YORK 10036

NAME OF SUBMITTER:	CHRISTINE SUN
SIGNATURE:	/christine sun/
DATE SIGNED:	09/29/2016
Total Attachments: 13 source=Patent Short Form#page1.tif source=Patent Short Form#page2.tif source=Patent Short Form#page3.tif source=Patent Short Form#page4.tif source=Patent Short Form#page5.tif source=Patent Short Form#page6.tif source=Patent Short Form#page7.tif source=Patent Short Form#page8.tif source=Patent Short Form#page9.tif source=Patent Short Form#page10.tif source=Patent Short Form#page11.tif source=Patent Short Form#page12.tif source=Patent Short Form#page13.tif	

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT, dated as of December 31, 2015 (such date, the “Effective Date”, and such agreement, this “Patent Assignment”), is entered into by and between Warner Chilcott Company, LLC, a Puerto Rican corporation, having its principal executive offices at 365 San Francisco Street, Penthouse, Old San Juan, Puerto Rico 00901 (“Assignor”) and Allergan Pharmaceuticals International Limited, an Irish company, having its principal executive offices at Clonsaugh Industrial Estate, Coolock, Dublin 17, Ireland (“Assignee”).

WITNESSETH:

WHEREAS, Assignor owns the patents and patent applications set forth on Schedule A, (the “Assigned Patents”); and

WHEREAS, Assignor desires to assign, transfer, convey and deliver to Assignee, and Assignee wishes to acquire from Assignor, all of its right, title and interest in and to the Assigned Patents;

NOW, THEREFORE, in consideration of one dollar (USD \$1.00) and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

1. Assignment. As of the Effective Date, Assignor hereby irrevocably assigns, transfers, conveys and delivers to Assignee, and Assignee hereby accepts from Assignor, all right, title and interest that Assignor has in and to Assigned Patents, together with (a) all rights derived from the Assigned Patents, including the inventions claimed therein and any reissues, reexamination, divisions, continuations, continuations-in-part, extensions, renewals and counterparts of such Assigned Patents already granted and which may be granted thereon, (b) any past, present or future claims or causes of action (either in law or in equity) arising out of or related to any infringement of any of the Assigned Patents, and the right to sue for damages, injunctive relief or any other remedy or otherwise recover therefor, (c) any and all income, royalties, damages and payments now or hereafter due and/or payable with respect to the Assigned Patents and the right to receive such income, royalties and payments, (d) the right to prosecute, maintain and defend the Assigned Patents, (e) the right to claim priority based on any of the Assigned Patents and (f) the right to fully and entirely stand in the place of Assignor in all matters related thereto, the same to be held and enjoyed by Assignee for its own use and enjoyment and the use and enjoyment of its successors and assigns as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made. The assignment contemplated herein is meant to be an absolute assignment and not by way of security.

2. Authority. As of the Effective Date and until the earlier of (i) the date of recordal in the United States Patent and Trademark Office or, with respect to any Assigned Patent filed or registered in any jurisdiction outside the United States, in the corresponding entity or agency in any such applicable foreign country or multinational authority, of this Patent Assignment, and (ii) the date on which the Assignor is no longer a subsidiary of Allergan plc, the Assignee hereby authorizes the Assignor to take whatever steps the Assignor deems appropriate, on the Assignee’s behalf, to maintain the Assigned Patents in the respective jurisdictions.

3. Further Assurances. As may be necessary, Assignor shall execute, acknowledge and deliver such other instruments, documents and agreements and shall do such other things as may be

Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited – Patent Assignment
– United States

reasonably necessary, proper or advisable to carry out its obligations under this Agreement and as may be reasonably necessary, proper or advisable to more completely effectuate, consummate, record, perfect or confirm the transactions contemplated hereby. If Assignor fails to promptly take or execute any of the action or document described in this Section 3 after written request by Assignee, Assignor hereby constitutes and appoints Assignee as its true and lawful agent and attorney-in-fact, with full power of substitution, in the name and stead of Assignor but on behalf and for the benefit of Assignee, to take and execute in the name of Assignor any and all actions and documents that may be deemed proper to effectuate, consummate, record, perfect or confirm the transactions contemplated in this Patent Assignment.

4. Recordation. Assignee shall be solely responsible for all actions associated with the perfection of Assignee's right, title and interest in and to the Assigned Patents and recordation and/or registration of this Patent Assignment or any other document evidencing the assignment to Assignee of the Assigned Patents. The Assignor hereby authorizes the Director of Patents and Trademarks in the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign countries or multinational authorities, to record Assignee as the assignee and owner of the Assigned Patents and to deliver to Assignee, and to Assignee's attorneys, agents, successors or assigns, all official documents and communications as may be warranted by this Patent Assignment, including but not limited to issuing any and all Letters Patents of the United States (or corresponding documents in any applicable foreign countries) on inventions claimed in the Assigned Patents.


5. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

6. General Provisions. This Patent Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Patent Assignment delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Patent Assignment. This Patent Assignment is entered into pursuant to the Assignment Agreement entered into by and between Assignor and Assignee as of December 31, 2015 (the "IP Assignment Agreement"). To the extent of any conflict between this Patent Assignment and the IP Assignment Agreement, the IP Assignment Agreement will govern. Neither this Agreement nor any provision hereof shall be waived, amended, modified, changed, supplemented, discharged or terminated except by an instrument in writing executed by the parties. This Patent Assignment is binding upon and inures to the benefit of the parties hereto and their respective successors and assigns.

[Remainder of this page intentionally left blank]

IN WITNESS WHEREOF, the parties hereto have duly executed this Patent Assignment with effect as of the Effective Date.

WARNER CHILCOTT COMPANY, LLC


By: 
Name: FRANCISCO RODRIGUEZ
Title: GENERAL MANAGER

Signature Page for Warner Chilcott Company, LLC – Allergan Pharmaceuticals International
Limited – Patent Assignment – United States

PATENT
REEL: 040183 FRAME: 0135

IN WITNESS WHEREOF, the parties hereto have duly executed this Patent Assignment with effect as of the Effective Date.

ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED

By: 
Name: TOM NELLIGAN
Title: AUTHORIZED SIGNATORY

Signature Page for Warner Chilcott Company, LLC – Allergan Pharmaceuticals International
Limited – Patent Assignment – United States

Schedule A

LIST OF ASSIGNED PATENTS

Jurisdiction	Title	Assignor Entity	Application Number	Application Date	Patent Number	Issue Date
US	[(METHOXY(METHYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE AND METHODS OF USING THE SAME	Warner Chilcott Company, LLC	13/471275	14-May-2012		
US	5-AMINOSALICYLIC ACID CAPSULE FORMULATION	Warner Chilcott Company, LLC	14/474868	02-Sep-2014		
US	BISPHOSPHONATE COMPOUNDS	Warner Chilcott Company, LLC	12/912514	26-Oct-2010	8314081	20-Nov-2012
US	BISPHOSPHONATE COMPOUNDS	Warner Chilcott Company, LLC	13/650785	12-Oct-2012	8710215	29-Apr-2014
US	BISPHOSPHONATE COMPOUNDS	Warner Chilcott Company, LLC	14/205937	12-Mar-2014	8822435	02-Sep-2014
US	BLISTER CARD	Warner Chilcott Company, LLC	29/285645	04-Apr-2007	D562153	19-Feb-2008
US	CHEWABLE ORAL CONTRACEPTIVE	Warner Chilcott Company, LLC	09/879028	12-Jun-2001	6667050	23-Dec-2003
US	COMPOSITIONS CONTAINING 5-AMINO-2-HYDROXYBENOIC ACID AND A REDUCING SUGAR	Warner Chilcott Company, LLC	12/769293	28-Apr-2010		
US	COMPOSITIONS OF AZIMILDE DIHYDROCHLORIDE	Warner Chilcott Company, LLC	13/840612	15-Mar-2013	9035052	19-May-2015
US	COUPLING PROCESS FOR PREPARING QUINOLONE INTERMEDIATES	Warner Chilcott Company, LLC	12/258480	27-Oct-2008	8158798	17-Apr-2012
US	Derivative prodrugs of ethinyl estradiol	Warner Chilcott Company, LLC	11/478582	03-Jul-2006	7795241	14-Sep-2010
US	DI-STEROIDAL PRODRUGS OF ESTRADIOL	Warner Chilcott Company, LLC	11/009618	10-Dec-2004	7067505	27-Jun-2006
US	DI-STEROIDAL PRODRUGS OF	Warner Chilcott Company, LLC	11/009617	10-Dec-2004	7067504	27-Jun-2006

Schedule to Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited –
Patent Assignment – United States

Jurisdiction	Title	Assignor Entity	Application Number	Application Date	Patent Number	Issue Date
	ETHINYL ESTRADIOL					
US	DOSAGE FORMS OF BISPHOSPHONATE S	Warner Chilcott Company, LLC	11/106816	15-Apr- 2005	7645459	12-Jan- 2010
US	DOSAGE FORMS OF BISPHOSPHONATE S	Warner Chilcott Company, LLC	12/637100	14-Dec- 2009	8246989	21-Aug- 2012
US	DOSAGE FORMS OF BISPHOSPHONATE S	Warner Chilcott Company, LLC	13/544377	09-Jul-2012	8535718	17-Sep- 2013
US	DOSAGE FORMS OF RISEDRONATE	Warner Chilcott Company, LLC	11/286875	23-Nov- 2005	7645460	12-Jan- 2010
US	DOXYCYCLINE CALCIUM	Warner Chilcott Company, LLC	10/896045	22-Jul-2004	7485319	03-Feb- 2009
US	DOXYCYCLINE CALCIUM	Warner Chilcott Company, LLC	12/338491	18-Dec- 2008	8415331	09-Apr- 2013
US	Estrogen compositions for vaginal administration	Warner Chilcott Company, LLC	11/454697	16-Jun- 2006		
US	EXTENDED CYCLE MULTIPHASIC ORAL CONTRACEPTIVE METHOD	Warner Chilcott Company, LLC	11/078300	14-Mar- 2005	7569560	04-Aug- 2009
US	EXTENDED CYCLE MULTIPHASIC ORAL CONTRACEPTIVE METHOD	Warner Chilcott Company, LLC	12/534902	04-Aug- 2009	7935691	03-May- 2011
US	Extended cycle multiphasic oral contraceptive method	Warner Chilcott Company, LLC	11/704307	09-Feb- 2007	8063030	22-Nov- 2011
US	EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN	Warner Chilcott Company, LLC	11/112290	22-Apr- 2005	7704984	27-Apr- 2010
US	FILM-COATED TABLET FOR IMPROVED UPPER GASTROINTESTIN AL TRACT SAFETY	Warner Chilcott Company, LLC	09/095322	10-Jun- 1998	6165513	26-Dec- 2000
US	FILM-COATED TABLET FOR IMPROVED UPPER GASTROINTESTIN AL TRACT	Warner Chilcott Company, LLC	09/694799	23-Oct- 2000	6569460	27-May- 2003

Schedule to Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited –
Patent Assignment – United States

Jurisdiction	Title	Assignor Entity	Application Number	Application Date	Patent Number	Issue Date
	SAFETY					
US	FORMULATIONS AND METHODS OF TREATING INFLAMMATORY BOWEL DISEASE	Warner Chilcott Company, LLC	10/930743	01-Sep-2004	7737133	15-Jun-2010
US	FORMULATIONS AND METHODS OF TREATING INFLAMMATORY BOWEL DISEASE	Warner Chilcott Company, LLC	12/797655	10-Jun-2010	7928092	19-Apr-2011
US	Gel compositions for topical administration	Warner Chilcott Company, LLC	11/454717	16-Jun-2006		
US	GRADUATEDESTR OGEN CONTRACEPTIVE	Warner Chilcott Company, LLC	10/987653	12-Nov-2004	8124595	28-Feb-2012
US	GRADUATEDESTR OGEN CONTRACEPTIVE	Warner Chilcott Company, LLC	12/947397	16-Nov-2010	9132137	15-Sep-2015
US	IMPROVED VITAMIN D CONTENT UNIFORMITY IN PHARMACEUTICAL DOSAGE FORMS	Warner Chilcott Company, LLC	12/148987	24-Apr-2008	8703187	22-Apr-2014
US	Intravaginal drug delivery devices	Warner Chilcott Company, LLC	10/564031	09-Jul-2004		
US	Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs	Warner Chilcott Company, LLC	12/147310	26-Jun-2008	8962010	24-Feb-2015
US	INTRAVAGINAL MATRIX DRUG DELIVERY DEVICES	Warner Chilcott Company, LLC	10/472901	27-Mar-2003		
US	LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS	Warner Chilcott Company, LLC	12/637309	14-Dec-2009	8409614	02-Apr-2013
US	LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS	Warner Chilcott Company, LLC	12/638359	15-Dec-2009	8409615	02-Apr-2013
US	LOW-DOSE ESTRADIOL CREAM	Warner Chilcott Company, LLC	14/645512	12-Mar-2015		
US	MESALAMINE PHARMACEUTICAL COMPOSITION WITH MULTIPLE DOSAGE	Warner Chilcott Company, LLC	61/794998	15-Mar-2013		

Schedule to Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited –
Patent Assignment – United States

Jurisdiction	Title	Assignor Entity	Application Number	Application Date	Patent Number	Issue Date
	ELEMENTS FOR REDUCED DELIVERY VARIABILITY					
US	METHOD FOR IMPROVING COMPLIANCE WITH A TREATMENT REGIMEN FOR TREATING OR PREVENTING OSTEOPOROSIS	Warner Chilcott Company, LLC	13/325170	14-Dec-2011		
US	METHOD FOR MODULATING THE RELEASE OF MESALAMINE BY CONTROLLING TABLET HARDNESS	Warner Chilcott Company, LLC				
US	METHOD OF ENHANCING COGNITION	Warner Chilcott Company, LLC	08/872891	11-Jun-1997	5837724	17-Nov-1998
US	METHOD OF TREATING IRRITABLE BOWEL SYNDROME	Warner Chilcott Company, LLC	10/218735	13-Aug-2002	6653339	25-Nov-2003
US	METHOD OF TREATMENT	Warner Chilcott Company, LLC	12/397433	04-Mar-2009	8748476	10-Jun-2014
US	METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS	Warner Chilcott Company, LLC	09/799978	06-Mar-2001	6670140	30-Dec-2003
US	METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS	Warner Chilcott Company, LLC	10/649852	27-Aug-2003	7063954	20-Jun-2006
US	METHODS FOR IDENTIFYING COMPOUNDS FOR	Warner Chilcott Company, LLC	11/412025	26-Apr-2006	7572768	11-Aug-2009

Schedule to Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited –
Patent Assignment – United States

Jurisdiction	Title	Assignor Entity	Application Number	Application Date	Patent Number	Issue Date
	REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS					
US	METHODS OF (4S, 4aS, 5aR, 12aS)-4-DIMETHYLAMINO-3, 10, 12, 12a-TETRAHYDROXY-7- {(methoxy(METHYL) AMINO)-METHYL}-1, 11-DIOXO-1,4,4a,5,5a,6,11,12a-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE	Warner Chilcott Company, LLC	13/893717	14-May-2013		
US	METHODS OF TREATING OR PREVENTING OSTEOPOROSIS USING BISPHOSPHONATE S OR PHOSPHONOALYLPHOSPHINATES WITH LOW DOSES OF ESTROGEN	Warner Chilcott Company, LLC	08/008859	25-Jan-1993	6329354	11-Dec-2001
US	Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability	Warner Chilcott Company, LLC	11/955072	12-Dec-2007		
US	MODIFIED RELEASE FORMULATIONS AND METHODS OF TREATING INFLAMMATORY BOWEL DISEASE	Warner Chilcott Company, LLC	11/371958	10-Mar-2006	7825106	02-Nov-2010
US	ORAL PHARMACEUTICAL PRODUCTS CONTAINING 17 BETA-ESTRADIOL-3-LOWER ALLCANOATE, ...	Warner Chilcott Company, LLC	10/023748	21-Dec-2001	6962908	08-Nov-2005

Schedule to Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited –
Patent Assignment – United States

Jurisdiction	Title	Assignor Entity	Application Number	Application Date	Patent Number	Issue Date
US	ORAL PHARMACEUTICAL PRODUCTS CONTAINING 17 BETA-ESTRADIOL-3-LOWER ALLCANOATE, ...	Warner Chilcott Company, LLC	10/833997	21-Dec-2001	7572779	11-Aug-2009
US	ORAL PHARMACEUTICAL PRODUCTS CONTAINING 17 BETA-ESTRADIOL-3-LOWER ALLCANOATE, ...	Warner Chilcott Company, LLC	11/154704	17-Jun-2005	7799771	21-Sep-2010
US	PEPTIDES SELECTIVE AT THE CORTICOTROPIN RELEASING FACTOR 2-RECEPTOR	Warner Chilcott Company, LLC	10/317252	11-Dec-2002	6936585	30-Aug-2005
US	PEPTIDES SELECTIVE AT THE CORTICOTROPIN RELEASING FACTOR 2-RECEPTOR	Warner Chilcott Company, LLC	11/121612	04-May-2005	7462597	09-Dec-2008
US	PEPTIDES SELECTIVE AT THE CORTICOTROPIN RELEASING FACTOR 2-RECEPTOR	Warner Chilcott Company, LLC	10/317251	11-Dec-2002	7192924	20-Mar-2007
US	PEPTIDES SELECTIVE AT THE CORTICOTROPIN RELEASING FACTOR 2-RECEPTOR	Warner Chilcott Company, LLC	11/701576	02-Feb-2007	7608701	27-Oct-2009
US	PEPTIDES SELECTIVE AT THE CORTICOTROPIN RELEASING FACTOR 2-RECEPTOR	Warner Chilcott Company, LLC	12/605718	26-Oct-2009	7897731	01-Mar-2011
US	PEPTIDES SELECTIVE AT THE CORTICOTROPIN	Warner Chilcott Company, LLC	10/315964	11-Dec-2002	7192923	20-Mar-2007

Schedule to Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited –
Patent Assignment – United States

Jurisdiction	Title	Assignor Entity	Application Number	Application Date	Patent Number	Issue Date
	RELEASING FACTOR 2-RECEPTOR					
US	PEPTIDES SELECTIVE AT THE CORTICOTROPIN RELEASING FACTOR 2-RECEPTOR	Warner Chilcott Company, LLC	11/701912	02-Feb-2007	7632933	15-Dec-2009
US	PHARMACEUTICAL COMBINATIONS	Warner Chilcott Company, LLC	11/977,137	October 23, 2007		
US	PHARMACEUTICAL COMBINATIONS	Warner Chilcott Company, LLC	12/868,021	August 25, 2010		
US	PHARMACEUTICAL COMPOSITIONS	Warner Chilcott Company, LLC	11/140723	31-May-2005	7138405	21-Nov-2006
US	PHARMACEUTICAL DOSAGE FORM OF MESALAMINE CONTAINING MULTIPHASIC ENTERIC COATED TABLETS	Warner Chilcott Company, LLC	14/210850	14-Mar-2014		
US	PHARMACEUTICAL DOSAGE FORM WITH MULTIPLE COATINGS FOR REDUCED IMPACT OF COATING FRACTURES	Warner Chilcott Company, LLC	09/996555	15-Nov-2001	6893662	17-May-2005
US	PHARMACEUTICAL DOSAGE FORM WITH MULTIPLE COATINGS FOR REDUCED IMPACT OF COATING FRACTURES	Warner Chilcott Company, LLC	11/070995	03-Mar-2005	8580302	12-Nov-2013
US	PHARMACEUTICAL DOSAGE FORM WITH MULTIPLE COATINGS FOR REDUCED IMPACT OF COATING FRACTURES	Warner Chilcott Company, LLC	14/051950	11-Oct-2013	9089492	28-Jul-2015
US	Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures	Warner Chilcott Company, LLC	11/096,457	04-01-2005		
US	PHARMACEUTICAL FORMULATIONS	Warner Chilcott Company, LLC	09/029072	21-Aug-1996	6106864	22-Aug-2000

Schedule to Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited –
Patent Assignment – United States

Jurisdiction	Title	Assignor Entity	Application Number	Application Date	Patent Number	Issue Date
	CONTAINING DARIFENACIN					
US	PHARMACEUTICAL SOFT GELATIN CAPSULE DOSAGE FORM	Warner Chilcott Company, LLC	14/210630	14-Mar-2014		
US	PHARMACEUTICAL SOFT GELATIN CAPSULE DOSAGE FORM	Warner Chilcott Company, LLC	61/794813	15-Mar-2013		
US	PHARMACEUTICAL SOFT GELATIN CAPSULE DOSAGE FORM WITH MODIFIED GUAR GUM	Warner Chilcott Company, LLC	14/210680	14-Mar-2014		
US	PHARMACEUTICAL SOFT GELATIN CAPSULE DOSAGE FORM WITH MODIFIED GUAR GUM	Warner Chilcott Company, LLC	14/524512	27-Oct-2014		
US	PHARMACEUTICAL SOFT GELATIN CAPSULE DOSAGE FORM WITH MODIFIED GUAR GUM	Warner Chilcott Company, LLC	61/794906	15-Mar-2013		
US	PROCESS FOR CONTROLLING CRYSTAL STRUCTURE OF RISEDRONATE	Warner Chilcott Company, LLC	10/901692	29-Jul-2004	7002014	21-Feb-2006
US	PROCESS FOR MAKING GEMINAL BISPHOSPHONATES	Warner Chilcott Company, LLC	09/771899	29-Jan-2001	6562974	13-May-2003
US	PROSTAGLANDIN COMPOSITION AND METHODS OF TREATMENT FOR MALE ERECTILE DYSFUNCTION	Warner Chilcott Company, LLC	10/236485	06-Sep-2002	7105571	12-Sep-2006
US	PROSTAGLANDIN COMPOSITION AND METHODS OF TREATMENT FOR MALE ERECTILE DYSFUNCTION	Warner Chilcott Company, LLC	09/480738	10-Jan-2000	6323241	27-Nov-2001
US	PROSTAGLANDIN COMPOSITIONS AND METHODS OF	Warner Chilcott Company, LLC	09/947617	06-Sep-2001	6693135	17-Feb-2004

Schedule to Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited –
Patent Assignment – United States

Jurisdiction	Title	Assignor Entity	Application Number	Application Date	Patent Number	Issue Date
	TREATMENT FOR MALE ERECTILE DYSFUNCTION					
US	PYRROLIDINE DERIVATIVES	Warner Chilcott Company, LLC			5,233,053	August 3, 1993
US	PYRROLIDINE DERIVATIVES	Warner Chilcott Company, LLC			5,096,890	March 17, 1992
US	Quadruphasic continuous graduated estrogen contraceptive	Warner Chilcott Company, LLC	11/476675	29-Jun-2006	8461138	11-Jun-2013
US	SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID SODIUM AS THE HEMIPENTAHYDRATE OR MONOHYDRATE	Warner Chilcott Company, LLC	09/771825	29-Jan-2001	6410520	25-Jun-2002
US	STABLE HYDRATE OF A MUSCARINIC RECEPTOR ANTAGONIST	Warner Chilcott Company, LLC	10/396887	25-Mar-2003	6930188	16-Aug-2005
US	STABLE HYDRATE OF A MUSCARINIC RECEPTOR ANTAGONIST	Warner Chilcott Company, LLC	12/049660	17-Mar-2008	7696357	13-Apr-2010
US	THREE-DIMENSIONAL COORDINATES OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA (HIF-1 ALPHA)-PROYL HYDROXYLASE (EGLN1) AND USES THEREOF	Warner Chilcott Company, LLC	12/473536	28-May-2009	8050873	01-Nov-2011
US	Topical Compositions	Warner Chilcott Company, LLC	09/423715		6841161	

Schedule to Warner Chilcott Company, LLC – Allergan Pharmaceuticals International Limited –
Patent Assignment – United States